Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

517

Participants

Timeline

Start Date

May 7, 2020

Primary Completion Date

April 19, 2022

Study Completion Date

April 19, 2022

Conditions
SARS-CoV 2COVID19SARS (Severe Acute Respiratory Syndrome)Cytokine Release SyndromeCytokine Storm
Interventions
DRUG

BAT + Calcifediol

"The subject will be treated with the best available therapy, which will include any combination of drugs included in the current protocol of the Ministry of Health and/or complementary notes issued by the Spanish Agency of Medicines and Health Products (AEMPS) plus Calcifediol caps. 266 µg. According to the pharmacokinetics of Calcifediol evaluated in an inflammatory model, the posology will be~Start: 2 capsules Days 3, 7, 14, 21, 28: 1 capsule"

DRUG

BAT

The subject will be treated with the best available therapy, which will include any combination of drugs included in the current protocol of the Ministry of Health and/or complementary notes issued by the Spanish Agency of Medicines and Health Products (AEMPS).

Trial Locations (1)

14001

Hospital Universitario Reina Sofía, Córdoba

All Listed Sponsors
collaborator

Junta de Andalucia

OTHER_GOV

collaborator

Dynamic Solutions

INDUSTRY

collaborator

Faes Farma, S.A.

INDUSTRY

lead

Maimónides Biomedical Research Institute of Córdoba

OTHER